Abelacimab represents a promising next-generation anticoagulant with the potential to provide ‘hemostasis-sparing anticoagulation’: vital protection from arterial and venous thromboembolic events with a reduced risk of clinically significant bleeding.
Due to prevailing fears of bleeding, effective prevention of thromboembolic events through optimal anticoagulation remains a real-world unmet need.
Through targeting Factor XI, our vision is to pharmacologically ‘uncouple’ pathological thrombosis from physiological hemostasis, bringing the paradigm shift of ‘hemostasis-sparing’ anticoagulation within reach.
Abelacimab, with its novel dual activity against Factor XI and XIa, has the potential to turn our vision of hemostasis-sparing anticoagulation into reality.